Key result
Cardiac contractility modulation improved MLWHFQ scores (SMD -0.69, p=0.0008) but did not significantly affect 6MWD, HF hospitalizations, or mortality.
Why the study?
Cardiac contractility modulation is a device therapy for systolic HF with narrow QRS, but an updated assessment of its efficacy and safety in RCTs was needed.
Does cardiac contractility modulation improve functional status and clinical outcomes in patients with systolic heart failure and narrow QRS?
Comparison
CCM vs non-CCM
Design
Systematic review and meta-analysis of RCTs
Follow-up
Mean six months
Authors
Loading...
Supports CCM for quality-of-life gains in narrow-QRS HFrEF; challenges expectations of reduced hospitalizations or mortality.
Meta-Analysis (n=801)
Does cardiac contractility modulation improve functional status and clinical outcomes in patients with systolic heart failure and narrow QRS?
Standardized Mean Difference: -0.69
p-value: p=0.0008
Short-term CCM therapy improves quality of life in systolic heart failure patients with narrow QRS, but does not significantly reduce hospitalizations or mortality.
Mando et al. (2019) conducted a meta-analysis in Systolic heart failure with narrow QRS (n=801). Cardiac contractility modulation (CCM) vs. non-CCM was evaluated on Minnesota Living with Heart Failure Questionnaire (MLHFQ) (SMD -0.69, p=0.0008). Cardiac contractility modulation improved MLWHFQ scores (SMD -0.69, p=0.0008) but did not significantly affect 6MWD, HF hospitalizations, or mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: